SCHOTT MINIFAB’s Post

Self-driving development of perfusion processes for mAb production 'R&D is missing the necessary toolset to fully exploit the potential of parallel mini-bioreactor systems and speed-up the generation of knowledge to reach truly accelerated innovation' https://lnkd.in/ehkxmBec

Don't miss out on a fascinating #Webinar hosted by Life Science Group Ltd. and Jotbody, focusing on cutting-edge #ExtracellularVesicle #EV solutions. Featured in this session are two advanced EV kits recently unveiled at the International Society of Extracellular Vesicles Annual Meeting #ISEV2024: 1. EVcraft #SurfaceModification Kit: Designed for the covalent conjugation of any molecules on EV surfaces 2. EVfect #Transfection kit: Designed for the loading of various nucleic acids into any EV. These kits are set to transform therapeutic applications and research methods in the EV field. Join us to hear from the experts behind these innovations! Dr. Migara Jayasinghe (Jay) Jayasinghe will discuss the therapeutic potential of modified EVs, focusing on their use in targeted drug delivery and clinical applications. Additionally, Dr. Marco Pirisinu, Business Director at Jotbody, will introduce other solutions to simplify EV research. Event Details: Date: September 25, 2024 Time: 11 AM GMT Platform: Microsoft Teams Don't miss this chance to engage with experts and explore the future of EV technologies. Register now for an insightful session at https://lnkd.in/eRGH_vnj

Don't miss out on a fascinating hashtag #Webinar hosted by Life Science Group Ltd. and Jotbody, focusing on cutting-edge #ExtracellularVesicle #EV solutions. Featured in this session are two advanced EV kits recently unveiled at the International Society of Extracellular Vesicles Annual Meeting #ISEV2024: 1. EVcraft #SurfaceModification Kit: Designed for the covalent conjugation of any molecules on EV surfaces 2. EVfect #Transfection kit: Designed for the loading of small and big nucleic acids into any EV. These kits are set to transform therapeutic applications and research methods in the EV field. Join us to hear from the experts behind these innovations! Dr. Migara Jayasinghe (Jay) Jayasinghe will discuss the therapeutic potential of modified EVs, focusing on their use in targeted drug delivery and clinical applications. Additionally, Dr. Marco Pirisinu, Business Director at Jotbody, will introduce other solutions to simplify EV research. Event Details: Date: September 25, 2024 Time: 11 AM GMT Platform: Microsoft Teams Don't miss this chance to engage with experts and explore the future of EV technologies. Register now for an insightful session at https://lnkd.in/eRGH_vnj

Jason Gardner, Flagship CEO-Partner & CEO of #FlagshipFounded Ampersand Biomedicines discusses what drew him to Flagship and its ecosystem, leveraging data and AI with Ampersand's AND-Platform™, and why paranoid optimism is a key part of the culture at Flagship in this #BusinessofBiotech episode with Matthew Pillar. ⬇

Connect with Allumiqs to elevate your Omics research!

🔍 Volume displacement pulsatile VA #ECMO: preliminary data from in vitro study investigating novel pressure-sensitive #ECLS device using validated mock-circulation loop. This preclinical experiment demonstrated surplus hemodynamic energy production & left ventricular unloading vs continuous-flow pump. Open access #FOAMcc #FOAMecmo on ASAIO Journal 🔓 https://bit.ly/3TFTfEp

Specializing in pioneering non-invasive drug delivery solutions for ocular diseases, Mati Therapeutics integrated Mecademic ’s Meca500 robotic arm into their production lineup. Compact, precise, and cost-effective, the Meca500 has optimized Mati’s manufacturing processes, boosting output and company value. With over a decade of experience in crafting manufacturing equipment, Mati's transition from a Contract Manufacturing Organization to establishing an in-house production facility marks a significant milestone in their journey. By implementing the Meca500 in their processes, Mati was able to: ✅ Optimize manufacturing space with its compact size. ✅ Save on setup costs by ditching the separate controller. ✅ Trim waste and boost production efficiency with high accuracy. ✅ Facilitate swift integration and reduce downtime with short lead times. ✅ Quickly adapt to changing production demands, enhancing flexibility. Read more about this Mecademic case study by navigating to the link in the comments. #MatiTherapeutics #OcularHealth #Innovation #Automation #Meca500

The topic for this week’s The Kinetix Group-Powered by Petauri™ PACT Executive Briefing is, “What are Laboratory Benefit Managers...and why should I care...?” These Executive Briefings provide - in 3-minutes, or less - highlights on one of healthcare’s critical market access issues, policies, challenges, or trends. Laboratory Benefit Managers have emerged over the past decade to fill the need to manage complex and expensive laboratory testing for payers. They have become the new Precision Medicine Gatekeepers. Results from the approximately 14 billion annual diagnostic tests are estimated to influence over 70% of today’s clinical decisions. It’s estimated that there is both overutilization of testing in approximately 20% of cases, and underutilization of testing in approximately 45% of cases. Laboratory Benefit Managers have improved Next Generation Sequencing test payment turnaround times, but also have increased denial rates. Laboratory Benefit Managers may present another barrier for time-to-treatment-initiation in some patients. Check out The Kinetix Group-Powered by Petauri™ growing library of TKG PACT Executive Briefings where you can listen and download the companion PDF infographics. https://lnkd.in/evZKhgre #MarketAccess, #TKG, #TKGPACT, #Laboratory, #LabBenefitManager, #Drug, #LBM

NEW!! 💣 #StellarMS #ThermoScientific #MassSpectrometry 🎯 Moving biomarker candidates from discovery to validation more efficiently, confidently, and at lower cost requires breakthroughs in sensitivity, specificity, and throughput at scale. 🧪 Designed to verify more biomarkers in less time, the Thermo Scientific™ Stellar™ mass spectrometer introduces breakthrough technology combined with robust quantitation. Enhance certainty with the specificity of rapid full-scan MSn acquisition via hybrid linear ion trap technology. ⚙️ Streamline high-throughput generation of high-quality data with automated multi-analyte method creation and dynamic instrument control. 🚀 Compared to other technologies, the instrument delivers 10X sensitivity when targeting 5X more analytes using faster gradients, accelerating the transition from research to clinical trials. Learn more » https://lnkd.in/dycZFFeh #StellarMS #ThermoScientific #MassSpectrometry

"We have 3 pillars: Biology42, Chemistry42 and Medicine42. Now, all of those engines are run by the Copilot. They are instructional, and you can talk to them." Check the video of Alex Zhavoronkov, Founder and CEO of Insilico Medicine, as he dives deep into the three pillars of Pharma.ai Platforms. #PharmaRevolution #InnovationInHealthcare #PharmaTech